射波刀联合经肝动脉化疗栓塞治疗原发性肝癌患者疗效研究*

doi:10.3969/j.issn.1672-5069.2020.06.031

摘要/Abstract

摘要： 目的观察采用射波刀联合经肝动脉化疗栓塞(TACE)治疗原发性肝癌(PLC)患者的疗效。方法 2016年1月～2019年5月在我院肝病科和上海长海医院诊治的PLC患者58例,被随机分为TACE治疗组29例和TACE联合射波刀立体定向放射治疗29例。结果术后随访,联合组总有效率为82.8%,显著高于TACE组的58.6%(P<0.05);治疗后,联合组血清血管内皮生长因子(VEGF)水平为(200.4±20.6)pg/ml,显著低于TACE组【(326.5±31.5)pg/ml,P<0.05】,基质金属蛋白酶(MMP)水平为(30.16±28.9)ng/L,显著低于TACE组【(74.2±7.5)ng/L,P<0.05】,甲胎蛋白(AFP)水平为(632.5±60.3)μg/L,显著低于TACE组【794.6±71.8)μg/L,P<0.05】;治疗后,联合组血清丙氨酸氨基转移酶(ALT)水平为(48.4±2.7)U/L,显著高于TACE组【(35.4±4.0)U/L,P<0.05】;联合组不良反应发生率为44.8%,与TACE组的48.3%比,无显著性差异(P>0.05)。结论采用TACE联合射波刀立体定向放射治疗PLC患者具有较好的临床疗效,其远期效果还有待于进一步观察。

关键词: 原发性肝癌, 经肝动脉化疗栓塞, 射波刀立体定向放射治疗, 治疗

Abstract: Objective The aim of this study was to observe the short-term efficacy of cyberknife stereotactic radiotherapy (CSR) and transcatheter arterial chemoembolization(TACE) as the first line treatment for patients with primary liver cancer (PLC). Methods 58 patients with PLC were recruited in this study between January 2016 and May 2019, and were randomly divided into two groups. 29 patients received TACE and other 29 patients underwent TACE and CSR. Serum vascular endothelial growth factor (VEGF), matrix metalloproteinase (MMP) and AFP were detected. Results The total effective rate in TACE and CSR combination group was 82.8%, significantly higher than 58.6% in TACE-treated group (P<0.05); after treatment, serum VEGF level in the combination-treated group was (200.4±20.6) pg/ml, significantly lower than 【(326.5±31.5)pg/ml, P<0.05】, serum MMP level was (30.16±28.9)ng/L, significantly lower than 【(74.2±7.5)ng/L, P<0.05】, and serum AFP level was (632.5±60.3)μg/L, significantly lower than 【794.6±71.8)μg/L, P<0.05】 in the TACE-treated group; serum alanine aminotransferase level was (48.4±2.7)U/L, significantly higher than 【(35.4±4.0)U/L, P<0.05】 in TACE-treated group; the incidence of side effects was 44.8%, not significantly different compared to 48.3% in TACE-treated group (P>0.05). Conclusion The TACE and cyberknife stereotactic radiotherapy in treatment of patients with PLC non suitable for surgery has a good short-term clinical efficacy, which needs further investigation.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Cyberknife stereotactic radiotherapy, Therapy

胡侠, 翟笑枫, 顾伟, 卢成鸿. 射波刀联合经肝动脉化疗栓塞治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 881-884.

Hu Xia, Zhai Xiaofeng, Gu Wei, et al. Cyberknife stereotactic radiotherapy and transcatheter arterial chemoembolization as an option of treatment for patients with primary liver cancer[J]. Journal of Practical Hepatology, 2020, 23(6): 881-884.

参考文献

[1] Ma L, Wang B, Long Y, et al. Effect of traditional Chinese medicine combined with western therapy on primary hepatic carcinoma: a systematic review with meta-analysis. Front Med, 2017, 11(2): 191-202.
[2] Yamamoto M, Oshita A, Nishisaka T, et al. Synchronous double primary hepatic cancer consisting of hepatocellular carcinoma and cholangiolocellular carcinoma: a case report. J Med Case Rep, 2018, 12(1): 224.
[3] Chu HH, Gwon DI, Kim JH, et al. Drug-eluting microsphere versus cisplatin-based transarterial chemoembolization for the treatment of hepatocellular carcinoma: propensity score-matched analysis. Am J Roentgenol, 2020, 22(1): 1-8.
[4] Sui W, Gan Q, Liu F, et al. The differentially expressed circular ribonucleic acids of primary hepatic carcinoma following liver transplantation as new diagnostic biomarkers for primary hepatic carcinoma. Tumour Biol, 2018, 40(4): 1392322736.
[5] Nalichowski A, Kaufman I, Gallo J, et al. Single fraction radiosurgery/stereotactic body radiation therapy (sbrt) for spine metastasis: a dosimetric comparison of multiple delivery platforms. J Appl Clin Med Phys, 2017, 18(1): 164-169.
[6] Takaki H, Sato Y, Yamakado K. Transcatheter arterial chemoembolization for hepatocellular carcinoma:current topics. Nihon Shokakibyo Gakkai Zasshi, 2017, 114(9): 1602-1610.
[7] Maas M, Beets-Tan R, Gaubert JY, et al. Follow-up after radiological intervention in oncology: ecio-esoi evidence and consensus-based recommendations for clinical practice. Insights Aging,2020,11(1): 83.
[8] Pereira PL, Arnold D, de Baère T, et al. A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: design and rationale of cirel. Dig Liver Dis, 2020,30(1):S1590-8658.
[9] Pung L, Ahmad M, Mueller K, et al. The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Vasc Interv Radiol, 2017, 28(3): 334-341.
[10] Jung E, Shin J H, Kim J H, et al. Arterial dissections during transcatheter arterial chemoembolization for hepatocellular carcinoma: a 19-year clinical experience at a single medical institution. Acta Radiol, 2017, 58(7): 842-848.
[11] Yoo SH, Kwon JH, Nam SW, et al. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-flurouracil versus sorafenib for hepatocellular carcinoma with refractoriness of transarterial chemoembolization using doxorubicin. Cancer Control, 2020, 27(2): 1073274820935843.
[12] Lanza E, Masetti C, Messana G, et al. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS One, 2020,15(6): e0232371.
[13] Ding C, Saw C B, Timmerman R D. Cyberknife stereotactic radiosurgery and radiation therapy treatment planning system. Med Dosim, 2018, 43(2): 129-140.
[14] Manabe Y, Murai T, Ogino H, et al. CyberKnife stereotactic radiosurgery and hypofractionated stereotactic radiotherapy as first-line treatments for imaging-diagnosed intracranial meningiomas. Neurol Med Chir (Tokyo), 2017, 57(12): 627-633.
[15] Zhu X, Li F, Ju X, et al. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Cancer Med, 2017, 6(10): 2263-2270.
[16] Di Franco R, Borzillo V, Ravo V, et al. Radiosurgery and stereotactic radiotherapy with cyberknife system for meningioma treatment. Neuroradiol J, 2018, 31(1): 18-26.
[17] Zhou TY, Zhou GH, Zhang YL, et al. Drug-eluting beads transarterial chemoembolization with callispheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. J Cancer, 2020, 11(15): 4534-4541.
[18] Nakamura M, Nishimura H, Mayahara H, et al. Investigation of the efficacy and safety of cyberKnife hypofractionated stereotactic radiotherapy for brainstem metastases using a new evaluation criterion: 'symptomatic control'. J Radiat Res, 2017, 58(6): 834-839.
[19] Yamazaki H, Ogita M, Himei K, et al. Carotid blowout syndrome in pharyngeal cancer patients treated by hypofractionated stereotactic re-irradiation using cyberknife: a multi-institutional matched-cohort analysis. Radiother Oncol, 2015, 115(1): 67-71.
[20] Napieralska A, Miszczyk L, Stapor-Fudzinska M. Cyberknife stereotactic ablative radiotherapy as an option of treatment for patients with prostate cancer having oligometastatic lymph nodes: single-center study outcome evaluation. Technol Cancer Res Treat, 2016, 15(5): 661-673.

射波刀联合经肝动脉化疗栓塞治疗原发性肝癌患者疗效研究^*

Cyberknife stereotactic radiotherapy and transcatheter arterial chemoembolization as an option of treatment for patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李晓燕, 胡和平. 加强肝癌内科队伍建设,重视肝癌内科规范化和个性化诊疗决策[J]. 实用肝脏病杂志, 2021, 24(1): 1-3.
[2]	周新民, 丁小鹏. 基础肝病治疗在原发性肝癌综合治疗中的重要作用[J]. 实用肝脏病杂志, 2021, 24(1): 4-6.
[3]	刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 7-9.
[4]	郑志恒, 李维筠, 回振宇, 陈莹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及血清Pygo2和GP73水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 19-22.
[5]	林金祥, 杨可立. PEG-IFNα-2a与PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 27-30.
[6]	樊秉栋, 张国华, 王君. 索磷布韦/维帕他韦联合利巴韦林治疗慢性丙型肝炎患者疗效临床研究[J]. 实用肝脏病杂志, 2021, 24(1): 31-34.
[7]	杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.
[8]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[9]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[10]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[11]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[12]	蔡宇, 王孟春, 邱新平, 张宁宁, 刘丽莉, 吴博, 杨奇. 复方甘草酸苷联合丁二磺酸腺苷蛋氨酸治疗酒精性肝炎伴胆汁淤积患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 71-74.
[13]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[14]	李庆玲, 何树光, 易小明, 段婷娜, 周意. 雷公藤多甙联合异甘草酸镁治疗自身免疫性肝炎患者外周血淋巴细胞PD-1和PD-L1变化[J]. 实用肝脏病杂志, 2021, 24(1): 79-82.
[15]	曾娇, 郭贵海. 聚乙二醇与乳果糖治疗肝性脑病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2021, 24(1): 99-102.